FDA approves rixubis for prophylactic tx in hemophilia B

(HealthDay)—Rixubis (coagulation factor IX recombinant) has been approved by the U.S. Food and Drug Administration to prevent routine bleeding episodes in people aged 16 and older with hemophilia B, the agency said in a news release.

It's the first recombinant coagulation factor IX to be sanctioned by the FDA. People with B, mostly males, have a that leads to a deficiency in factor IX. Affecting some 3,300 people in the United States, the disorder can cause serious bleeding episodes, most commonly affecting the joints, the agency said.

Rixubis is a purified protein supplied as a freeze-dried powder. It is injected twice weekly after being combined with sterilized water.

The treatment was evaluated in clinical studies involving 73 males between the ages of 12 and 65. Those who received the treatment had a 75 percent lower annual bleeding rate than those who had historically received on-demand treatment, the FDA said.

The treatment may lead to life-threatening in some recipients, the agency warned. More common clinical side effects included distorted taste, extremity pain, and atypical blood test results.

Rixubis is produced by Baxter Healthcare, based in Westlake Village, Calif.

More information: More Information

Related Stories

Simponi approved for ulcerative colitis

date May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Xgeva approved for rare, non-malignant tumor

date Jun 13, 2013

(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

Kcentra approved to stop severe bleeding in heart patients

date Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.